The abstract is read at the publisher; the summary is JClub's.
VINCIT, an injectable nanofiber hydrogel composite, enables localized in vivo CAR T cell engineering, extending median survival in a humanized lymphoma mouse model from 32 to 110 days after one dose.
- Why it matters: Systemic viral delivery for in vivo CAR T generation is constrained by off-target exposure and poor access to target immune cells, limiting safe and efficient engineering.
- What they did: The authors developed VINCIT to spatially retain viral vectors and recruit endogenous immune cells for local T cell transduction, comparing it with intravenous viral delivery and subcutaneous free virus.
- The result: VINCIT confines transgene expression versus intravenous delivery, increases T cell transduction versus subcutaneous free virus, and generates CAR T cells that mediate CD19+ B cell depletion and sustained tumor control; neutrophil depletion reduces recruitment and T cell programming.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.